Vijay Pande
Bio + Health

Vijay Pande



More About Vijay

Vijay Pande, PhD, is a General Partner and has been at Andreessen Horowitz since 2014.  He founded and leads a16z Bio + Health, which invests in life sciences and healthcare through four dedicated funds with more than $3 billion under management. Vijay leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. He is also an Adjunct Professor of Structural Biology at Stanford University. He currently sits on the boards of Apeel Sciences, BioAge, Devoted Health, Freenome, Genesis Therapeutics, Insitro, Inceptive Therapeutics, Nautilus Biotechnology, Nobell, Omada Health,, and SciFi Foods, Scribe Therapeutics.

Prior to joining Andreessen Horowitz, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications and six patents). Vijay was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country. Vijay also co-founded Globavir Biosciences, and founded the Folding@Home Distributed Computing Project.

Vijay holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation, a Guinness World Record for Folding@Home, the American Chemical Society Thomas Kuhn Paradigm Shift Award, and was selected for MIT TR10.  In his teens, Vijay was the first employee at video game startup Naughty Dog, maker of Crash Bandicoot and The Last of Us.

Featured Content

  • Digital Biology New
    Daphne Koller and Vijay Pande

    Daphne Koller, founder and CEO of insitro, discusses how an LLM for cells could revolutionize drug discovery and how to bridge the technological and cultural divide between building with atoms and building with bits.

  • Commercializing AI in Healthcare: The Jobs to be Done New
    Jay Rughani, Daisy Wolf, Vijay Pande, and Julie Yoo

    Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.

  • We believe that any new technology has to be 10 times better to successfully displace the last one – marginal improvements aren’t worth the effort. Enterprise software struggled to clear that 10x bar in healthcare; AI clears it easily.

  • Washington: Will You Let AI Make Us Healthier?
    Colin Rom, Jeff Clark, Jay Rughani, and Vijay Pande

    The world is amidst an AI-driven industrial revolution. Whether we let it improve the health of Americans is up to how we regulate it. There is no sector where AI can drive more immediate, life-saving impact than in biotechnology and healthcare.

  • AI will have the greatest impact on life sciences and health when it can succeed at specialist tasks like diagnoses and medical procedures.

Load More

Select Investments

Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here:

go to top